7/10/2019 MiMedx: Undisclosed Details Undermine 'Independent' Investigation - MiMedx Group, Inc. (OTCMKTS:MDXG) | Seeking Alpha


https://seekingalpha.com/article/4109861-mimedx-undisclosed-details-undermine-independent-investigation 1/9


Short Ideas  |  Healthcare   |  Editors' Picks


MiMedx: Undisclosed Details Undermine 'Independent' Investigation
Sep. 27, 2017 12:50 PM ET18 comments
by: Aurelius


Summary


CEO Pete Petit has touted the purported independence of MiMedx's internal
investigation. But it was led by Petit's Fraternity 'Little Brother', the Chairman of the
Audit Committee.


MiMedx has declared that "independent outside legal counsel" conducted the
investigation. However, this supposedly independent law firm has represented
MiMedx and other Petit companies for years.


Although Petit claims that the board's investigative report was made public months
ago, MiMedx shielded it from investors through a confidential treatment request
submitted to the SEC in April.


To honor his word, Mr. Petit must immediately release the board's report in its
entirety along with an analysis purportedly conducted by a revenue recognition
expert.


If we misrepresent facts or lie, as a company official, [I] can go to jail


­Pete Petit, per earnings transcript published by Bloomberg


We fear that unsuspecting investors have relied on misrepresentations by MiMedx
(OTC:MDXG).



https://seekingalpha.com/stock-ideas/short-ideas

https://seekingalpha.com/stock-ideas/healthcare

https://seekingalpha.com/stock-ideas/editors-picks

https://seekingalpha.com/symbol/MDXG
7/10/2019 MiMedx: Undisclosed Details Undermine 'Independent' Investigation - MiMedx Group, Inc. (OTCMKTS:MDXG) | Seeking Alpha


https://seekingalpha.com/article/4109861-mimedx-undisclosed-details-undermine-independent-investigation 2/9


Last week, we released a report exposing undisclosed entanglements with distributors
who, according to whistleblower allegations, are being used by MiMedx to manipulate its
financials.


Viceroy Research released a report alleging that MiMedx has employed kickback &
bribery scheme inducers who came from Advanced BioHealing (ABH).


MiMedx has characterized the reports and whistleblower allegations as false. Last
Thursday, management held a conference call to address "short selling matters and
proactive remedies."


Instead of responding to each of the specific allegations during the call, Mr. Petit
repeatedly touted his exoneration by an internal investigation that was purportedly led by
independent parties.


But we uncovered undisclosed details that, in our opinion, directly undermine the
credibility of both the internal investigation and MiMedx's public statements to investors.


Note: MiMedx did not respond to a request for comment on items discussed in this report


MiMedx's "Independent" Investigation Was Led By Pete Petit's
Fraternity 'Little Brother'


After whistleblower allegations of channel stuffing first emerged last December, MiMedx's
Audit Committee commenced an internal investigation that cleared management of
wrongdoing.


The investigation, and the purported involvement of independent parties, was summarized
in last week's press release announcing receipt of an SEC subpoena:


Source: MiMedx Press Release



http://www.aureliusvalue.com/research/mimedx-flying-close-sun/

http://aureliusvalue.com/content/uploads/2017/09/502016CA013806XXXXMB_95-003-Copy.pdf

https://viceroyresearch.files.wordpress.com/2017/09/final-mimedx-part-1-report.pdf

http://www.policymed.com/2017/01/largest-settlement-in-medical-device-announced-.html

http://www.prnewswire.com/news-releases/mimedx-responds-to-deceptive-short-seller-reports-300523150.html

https://www.thestreet.com/story/14312588/1/mimedx-to-host-shareholder-call-on-september-21-2017-to-update-progress-on-various-strategic-initiatives-and-respond-to-topics-requested-by-shareholders.html

http://www.halunenlaw.com/whistleblowers-claim-mimedx-group-inc-defrauded-investors-in-lawsuit-filed-by-halunen-law/

http://phx.corporate-ir.net/phoenix.zhtml?c=213465&p=irol-newsArticle&ID=2302107

http://phx.corporate-ir.net/phoenix.zhtml?c=213465&p=irol-newsArticle&ID=2302107

https://static.seekingalpha.com/uploads/2017/9/23/38682326-15061942369004073_origin.png
7/10/2019 MiMedx: Undisclosed Details Undermine 'Independent' Investigation - MiMedx Group, Inc. (OTCMKTS:MDXG) | Seeking Alpha


https://seekingalpha.com/article/4109861-mimedx-undisclosed-details-undermine-independent-investigation 3/9


On last Thursday's conference call, Mr. Petit championed the investigation as making him
"very comfortable" and said:


believe me, this board is a group of individuals that are very independent of
this management group


The Chairman of the Audit Committee, by definition, should be independent of
management because shareholders rely on him as a key "gatekeeper" to prevent and
deter accounting fraud. MiMedx's Audit Chairman is a man named J. Terry Dewberry.


Mr. Dewberry happens to be Pete Petit's Fraternity Little Brother at Georgia Tech's Pi
Kappa Phi.


In a 2014 fraternity profile, Mr. Petit explains that the two have been "very close" for
decades and that Dewberry has "been a member of the executive team for all of our
businesses over the years."


Source: The Iotan Fall 2014 Newsletter


The frat even named Mr. Dewberry as helping coordinate a 2014 award for Mr. Petit.



https://www.sec.gov/news/testimony/031915-test.html

http://www.pikapp.net/uploads/6/0/1/0/6010658/fall_2014_iotan.pdf

http://www.pikapp.net/uploads/6/0/1/0/6010658/fall_2014_iotan.pdf
7/10/2019 MiMedx: Undisclosed Details Undermine 'Independent' Investigation - MiMedx Group, Inc. (OTCMKTS:MDXG) | Seeking Alpha


https://seekingalpha.com/article/4109861-mimedx-undisclosed-details-undermine-independent-investigation 4/9


Source: The Iotan Fall 2014 Newsletter, Cherrylion (Bronze Bust)


The two fraternity brothers have a remarkable history of working at the same companies
together. After both worked at Lockheed, the frat's profile of Mr. Dewberry explains that he
joined Healthdyne in 1981, a company founded by Petit that would later become Matria
through a merger. Dewberry worked at Healthdyne for 15 years before joining the board of
Matria and then following Petit to MiMedx.


Source: The Iotan Winter 2010 Newsletter


We find all this particularly problematic because, as explained in MiMedx's own filings,
Directors are only considered independent if they:


are free of any relationship that would interfere with the exercise of their independent
judgement.


Yet Mr. Petit is actively touting the independence of an investigation that, in reality, was led
by someone he has a close relationship with.



http://www.pikapp.net/uploads/6/0/1/0/6010658/fall_2014_iotan.pdf

http://cherrylion.com/wp-content/themes/powerhouseCenter/images/portfolio/tn/portrait26.jpg

https://issuu.com/pikappaphi/docs/iota_winter2010

https://www.sec.gov/Archives/edgar/data/1007228/000095014408003843/g13311esv8pos.htm

https://issuu.com/pikappaphi/docs/iota_winter2010

https://www.sec.gov/Archives/edgar/data/1376339/000137633916000155/mdxg-20160412xdef14a.htm
7/10/2019 MiMedx: Undisclosed Details Undermine 'Independent' Investigation - MiMedx Group, Inc. (OTCMKTS:MDXG) | Seeking Alpha


https://seekingalpha.com/article/4109861-mimedx-undisclosed-details-undermine-independent-investigation 5/9


Misrepresentations Concerning The Board's "Independent Outside
Legal Counsel"


MiMedx repeated in last Thursday's press release that the audit committee worked closely
with purported "independent outside legal counsel" to complete its investigation. But in
conversations with other investors, MiMedx has revealed that this firm is Troutman
Sanders.


Troutman Sanders has lengthy ties to Pete Petit and Terry Dewberry, having represented
and defended Healthdyne and later Matria. In fact, the firm's founder, Carl E. Sanders,
was also a Director of both Healthdyne and Matria.


Another "independent" member of the audit committee, Joseph G Bleser, was the CFO of
Healthdyne Information Enterprises when Petit, Bleser, and Sanders were Directors.
Bleser was also a Director at Matria where, of course, MiMedx Director and
President/COO Bill Taylor also came from.


Sometime after Petit joined MiMedx, Troutman began representing the company. A 2014
SEC filing, for example, reveals that Troutman "acted as counsel" for MiMedx's stock
incentive plan registration.



http://www.prnewswire.com/news-releases/mimedx-provides-information-on-its-interaction-with-the-sec-300523565.html

https://www.troutman.com/doug_salyers/

https://www.troutman.com/james_lamberth/

https://www.sec.gov/Archives/edgar/data/1007228/000095014405007573/g96357s3exv5w1.htm

http://www.legacy.com/obituaries/atlanta/obituary.aspx?pid=173210965

https://www.bloomberg.com/research/stocks/private/person.asp?personId=672603&privcapId=636325

http://people.equilar.com/bio/carl-sanders-matria-healthcare/salary/63083

https://www.sec.gov/Archives/edgar/data/1376339/000137633915000046/mdxg-20150403xdef14a.htm

https://www.sec.gov/Archives/edgar/data/1000231/0000950144-98-005705.txt

http://edgar.secdatabase.com/1779/95014496007424/filing-main.htm

https://www.sec.gov/Archives/edgar/data/1007228/000095014408003844/g13311fsv8pos.htm

https://www.linkedin.com/in/billtaylorpresident/

https://www.sec.gov/Archives/edgar/data/1376339/000137633914000039/mdxg_s8x11032014.htm
7/10/2019 MiMedx: Undisclosed Details Undermine 'Independent' Investigation - MiMedx Group, Inc. (OTCMKTS:MDXG) | Seeking Alpha


https://seekingalpha.com/article/4109861-mimedx-undisclosed-details-undermine-independent-investigation 6/9


Source: 2014 MiMedx SEC Filing and Exhibit


A Troutman attorney named David W. Ghegan, who previously represented Matria, is
specifically named in several other MiMedx filings. In addition to documents related to the
recent divestiture of Stability Biologics, Mr. Ghegan was copied on MiMedx
correspondence earlier this year related to a series of SEC comment letters.


So how could MiMedx call its own securities lawyers independent?


This fact pattern reminds us of Banc of California which, in an attempt to discredit our
report, falsely declared that the bank's internal investigation was led by independent
counsel.


The bank later admitted it made false statements to investors and that the investigation
was really led by lawyers who had previously represented the company and CEO. A new
investigation was begun by counsel with no previous ties to the company and the CEO
was quickly ousted amidst an SEC investigation.



https://www.sec.gov/Archives/edgar/data/1376339/000137633914000039/mdxg_s8x11032014.htm

https://www.sec.gov/Archives/edgar/data/1376339/000137633914000039/exhibit51opinionoftroutman.htm

https://www.troutman.com/david_ghegan

https://seekingalpha.com/filing/3683746

https://www.sec.gov/Archives/edgar/data/1376339/000137633917000014/filename1.htm

https://seekingalpha.com/instablog/38682326-aurelius/4926308-banc-response

http://www.prnewswire.com/news-releases/banc-of-california-board-provides-update-on-independent-investigation-plans-improvements-to-corporate-governance-policies-300394631.html

http://www.latimes.com/business/la-fi-sugarman-resignation-20170123-story.html

https://static.seekingalpha.com/uploads/2017/9/26/38682326-15064808384596078_origin.png
7/10/2019 MiMedx: Undisclosed Details Undermine 'Independent' Investigation - MiMedx Group, Inc. (OTCMKTS:MDXG) | Seeking Alpha


https://seekingalpha.com/article/4109861-mimedx-undisclosed-details-undermine-independent-investigation 7/9


Source: Banc of California Press Release


Where Is The Board's Investigative Report?


During last Thursday's call, Petit also declared that "we have also been very open and
transparent with our shareholders." Petit claimed that:


the board's report is public. We made that public many, many months ago.


But we could not locate the board's report on either MiMedx's website or within any of its
SEC filings. MiMedx did not respond to a request seeking the location of the board's
report.


The SEC asked for the Executive Summary of the Audit Committee's findings in one of its
comment letters from April 2017. However, MiMedx requested confidential treatment
which has shielded investors from seeing it.


Source: April 2017 SEC Comment Letter


As far as we can tell, details of the investigation were briefly summarized in two press
releases.


On December 27th, a mere twelve days after the whistleblower suit was filed, MiMedx
announced "preliminary investigation findings" that no changes to previously issued
financial statements would be necessary.



http://www.prnewswire.com/news-releases/banc-of-california-board-provides-update-on-independent-investigation-plans-improvements-to-corporate-governance-policies-300394631.html

https://www.sec.gov/Archives/edgar/data/1376339/000137633917000066/filename1.htm

https://www.sec.gov/Archives/edgar/data/1376339/000137633917000066/filename1.htm

http://www.halunenlaw.com/whistleblowers-claim-mimedx-group-inc-defrauded-investors-in-lawsuit-filed-by-halunen-law/

http://phx.corporate-ir.net/phoenix.zhtml?c=213465&p=irol-newsArticle&ID=2232886

https://static.seekingalpha.com/uploads/2017/9/26/38682326-15064820213850827_origin.png
7/10/2019 MiMedx: Undisclosed Details Undermine 'Independent' Investigation - MiMedx Group, Inc. (OTCMKTS:MDXG) | Seeking Alpha


https://seekingalpha.com/article/4109861-mimedx-undisclosed-details-undermine-independent-investigation 8/9


Then, a March 1st press release briefly summarized the board's final conclusion that
"there is no credible evidence of any wrongdoing on behalf of MiMedx management."


MiMedx has subsequently claimed that the investigation purportedly involved a "nationally
recognized expert on revenue recognition who reviewed and confirmed the Company's
revenue recognition practices to be proper."


But what is the name of this expert and where is his/her analysis? Did these parties also
review MiMedx's relationships with CPM Medical, SLR Medical, Spinelogix, and other
distributors?


These questions and others are precisely why Mr. Petit must honor his word and
immediately release the board's report (including the expert's analysis) in its
entirety.


Conclusion


In our opinion, the undisclosed details discussed in this report undermine the credibility of
MiMedx's internal investigation and the company's public statements to investors.


This is especially troubling because MiMedx has disclosed the receipt of a subpoena from
the SEC after the emergence of serious allegations of channel stuffing. Furthermore, the
company has disclosed that terminated individuals have "provided gifts and meals to
employees of the VA" and that one former employee has now pled "the fifth amendment
rather than answer questions related to dinners provided to doctors."


In light of these significant risks, we believe MiMedx is simply uninvestible.


Disclosure: I am/we are short MDXG. I wrote this article myself, and it expresses my own opinions. I am not receiving
compensation for it. I have no business relationship with any company whose stock is mentioned in this article.


Additional disclosure: IMPORTANT. The information set forth in this report does not constitute a recommendation to
buy or sell any security. This report represents the opinion of the author as of the date of this report. This report contains
certain “forward­looking statements,” which may be identified by the use of such words as “believe,” “expect,”
“anticipate,” “should,” “planned,” “estimated,” “potential,” “outlook,” “forecast,” “plan” and other similar terms. All are
subject to various factors, any or all of which could cause actual events to differ materially from projected events. This
report is based upon information reasonably available to the author and obtained from sources the author believes to be
reliable; however, such information and sources cannot be guaranteed as to their accuracy or completeness. The author
makes no representation as to the accuracy or completeness of the information set forth in this report and undertakes no
duty to update its contents. The author encourages all readers to do their own due diligence. 
You should assume that as of the publication date of his reports and research, Aurelius and possibly any companies
affiliated with him and their members, partners, employees, consultants, clients and/or investors (the “Aurelius Affiliates”)
have a short position in the stock (and/or options, swaps, and other derivatives related to the stock) and bonds of
MiMedx. They therefore stand to realize significant gains in the event that the prices of either equity or debt securities of
Mimedx decline. Aurelius and the Aurelius Affiliates intend to continue transactions in the securities of Mimedx for an
indefinite period after his first report on a subject company at any time hereafter regardless of initial position and the
views stated in Aurelius’ research. Aurelius will not update any report or information on this website to reflect such



http://phx.corporate-ir.net/phoenix.zhtml?c=213465&p=irol-newsArticle&ID=2250881

http://www.prnewswire.com/news-releases/mimedx-provides-update-on-litigation-with-terminated-employees-300506088.html

http://www.prnewswire.com/news-releases/mimedx-reports-further-developments-in-its-civil-litigation-against-former-employees-300515713.html
7/10/2019 MiMedx: Undisclosed Details Undermine 'Independent' Investigation - MiMedx Group, Inc. (OTCMKTS:MDXG) | Seeking Alpha


https://seekingalpha.com/article/4109861-mimedx-undisclosed-details-undermine-independent-investigation 9/9


positions or changes in such positions. 
Please note that Aurelius, the author of this report, and the “Aurelius Affiliates” are not in any way associated with
Aurelius Capital Management, LP, a private investment firm based in New York, and any affiliates of or funds managed
by the latter company.


JOIN THE CONVERSATION


Comments (18)


bcctex@gmail.com
I wish the SEC would investigate Aurelius and the other shorts


27 Sep 2017, 12:43 PM



https://seekingalpha.com/user/7437101
